Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Dec;85(12):1871–1877. doi: 10.1054/bjoc.2001.2169

Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes

A Håkansson 1, B Gustafsson 2, L Krysander 3, B Hjelmqvist 4, B Rettrup 4, L Håkansson 1
PMCID: PMC2364006  PMID: 11747328

Abstract

The therapeutic efficacy of biochemotherapy in metastatic malignant melanoma still carries a low remission rate, but with some durable responses. It would therefore be of considerable importance if patients with a high probability of responding could be identified using predictive tests. The response to interferon-alpha (IFN-α) correlates with the occurrence of CD4+ lymphocytes identified by fine-needle aspirates from melanoma metastases (Håkansson et al, 1996). The present investigation studies a possible correlation between tumour-infiltrating CD4+ lymphocytes in malignant melanoma metastases and the therapeutic effect of biochemotherapy. A total of 25 patients with systemic and 16 with regional metastatic melanoma were analysed before initiation of biochemotherapy (cis-platinum 30 mg/m2 d.1–3, DTIC 250 mg/m2 d.1–3 i.v. and IFN-α2b 10 million IU s.c. 3 days a week, q. 28d.). A monoclonal antibody, anti-CD4, was used to identify tumour-infiltrating lymphocytes in fine-needle aspirates before start of treatment. The presence of these lymphocytes was correlated to response, time to progression and overall survival. A statistically significant correlation (P = 0.01) was found between the occurrence of CD4+ lymphocytes and tumour regression during biochemotherapy in patients with systemic disease. Out of 14 patients with moderate to high numbers of infiltrating CD4+ lymphocytes, 12 achieved tumour regression. In contrast, among patients with low numbers of these cells in metastatic lesions, 8 out of 11 had progressive disease. We also found a significantly longer time to progression (P < 0.003) and overall survival (P < 0.01) among patients with moderate to high numbers of these cells compared to patients with low numbers of these cells before initiation of biochemotherapy. Furthermore, in patients with regional disease, we found a significantly longer time to progression (P = 0.01) and a trend toward a longer overall survival time (P = 0.09). Based on these results and as previously shown with IFN-α therapy alone, there seems to be a need for CD4+ lymphocytes infiltrating the tumours before the start of biochemotherapy to make the treatment successful. Determination of these cells in fine-needle aspirates seems to be a method to predict responders to biochemotherapy, thus increasing the cost–benefit of this treatment strategy considerably, both in terms of patient adverse reactions and health care costs. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: malignant melanoma, biochemotherapy, prediction of response, tumour-infiltrating lymphocytes (TILs)

Full Text

The Full Text of this article is available as a PDF (99.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arenberg D. A., Kunkel S. L., Burdick M. D., Standiford T. J., Strieter R. M. Regulation of monocyte-derived interleukin 1 receptor antagonist by cisplatinum. Cytokine. 1995 Jan;7(1):89–96. doi: 10.1006/cyto.1995.1012. [DOI] [PubMed] [Google Scholar]
  2. Balch C. M., Murad T. M., Soong S. J., Ingalls A. L., Halpern N. B., Maddox W. A. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978 Dec;188(6):732–742. doi: 10.1097/00000658-197812000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clark W. H., Jr, Elder D. E., Guerry D., 4th, Braitman L. E., Trock B. J., Schultz D., Synnestvedt M., Halpern A. C. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989 Dec 20;81(24):1893–1904. doi: 10.1093/jnci/81.24.1893. [DOI] [PubMed] [Google Scholar]
  4. Clemente C. G., Mihm M. C., Jr, Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996 Apr 1;77(7):1303–1310. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  5. Grob J. J., Dreno B., de la Salmonière P., Delaunay M., Cupissol D., Guillot B., Souteyrand P., Sassolas B., Cesarini J. P., Lionnet S. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998 Jun 27;351(9120):1905–1910. doi: 10.1016/s0140-6736(97)12445-x. [DOI] [PubMed] [Google Scholar]
  6. Halliday G. M., Patel A., Hunt M. J., Tefany F. J., Barnetson R. S. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg. 1995 May-Jun;19(3):352–358. doi: 10.1007/BF00299157. [DOI] [PubMed] [Google Scholar]
  7. Hansen M. G., McCarten A. B. Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck. Am J Surg. 1974 Oct;128(4):557–561. doi: 10.1016/0002-9610(74)90275-x. [DOI] [PubMed] [Google Scholar]
  8. Hernberg M., Turunen J. P., Muhonen T., Pyrhönen S. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother. 1997 Nov;20(6):488–495. doi: 10.1097/00002371-199711000-00009. [DOI] [PubMed] [Google Scholar]
  9. Håkansson A., Gustafsson B., Krysander L., Hjelmqvist B., Rettrup B., Håkansson L. On down-regulation of the immune response to metastatic malignant melanoma. Cancer Immunol Immunother. 1999 Aug;48(5):253–262. doi: 10.1007/s002620050573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Håkansson A., Gustafsson B., Krysander L., Håkansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res. 1998 Jan;18(1):33–39. doi: 10.1089/jir.1998.18.33. [DOI] [PubMed] [Google Scholar]
  11. Håkansson A., Gustafsson B., Krysander L., Håkansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer. 1996 Sep;74(5):670–676. doi: 10.1038/bjc.1996.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kang S., Barnhill R. L., Mihm M. C., Jr, Sober A. J. Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol. 1993 Apr;20(2):126–129. doi: 10.1111/j.1600-0560.1993.tb00228.x. [DOI] [PubMed] [Google Scholar]
  13. Keilholz U., Conradt C., Legha S. S., Khayat D., Scheibenbogen C., Thatcher N., Goey S. H., Gore M., Dorval T., Hancock B. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol. 1998 Sep;16(9):2921–2929. doi: 10.1200/JCO.1998.16.9.2921. [DOI] [PubMed] [Google Scholar]
  14. Khayat D., Borel C., Tourani J. M., Benhammouda A., Antoine E., Rixe O., Vuillemin E., Bazex P. A., Thill L., Franks R. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 1993 Nov;11(11):2173–2180. doi: 10.1200/JCO.1993.11.11.2173. [DOI] [PubMed] [Google Scholar]
  15. Kirkwood J. M., Ibrahim J. G., Sondak V. K., Richards J., Flaherty L. E., Ernstoff M. S., Smith T. J., Rao U., Steele M., Blum R. H. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun;18(12):2444–2458. doi: 10.1200/JCO.2000.18.12.2444. [DOI] [PubMed] [Google Scholar]
  16. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7–17. doi: 10.1200/JCO.1996.14.1.7. [DOI] [PubMed] [Google Scholar]
  17. Larsen T. E., Grude T. H. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis. Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):523–530. [PubMed] [Google Scholar]
  18. Legha S. S. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol. 1997 Feb;24(1 Suppl 4):S39–S43. [PubMed] [Google Scholar]
  19. Legha S. S., Ring S., Papadopoulos N., Plager C., Chawla S., Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989 Nov 15;64(10):2024–2029. doi: 10.1002/1097-0142(19891115)64:10<2024::aid-cncr2820641010>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  20. McClay E. F., Mastrangelo M. J., Berd D., Bellet R. E. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer. 1992 Feb 20;50(4):553–556. doi: 10.1002/ijc.2910500410. [DOI] [PubMed] [Google Scholar]
  21. McGovern V. J. Spontaneous regression of melanoma. Pathology. 1975 Apr;7(2):91–99. doi: 10.3109/00313027509092702. [DOI] [PubMed] [Google Scholar]
  22. Mihm M. C., Jr, Clemente C. G., Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996 Jan;74(1):43–47. [PubMed] [Google Scholar]
  23. Mizutani Y., Yoshida O., Bonavida B. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). J Urol. 1998 Aug;160(2):561–570. [PubMed] [Google Scholar]
  24. Pehamberger H., Soyer H. P., Steiner A., Kofler R., Binder M., Mischer P., Pachinger W., Auböck J., Fritsch P., Kerl H. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998 Apr;16(4):1425–1429. doi: 10.1200/JCO.1998.16.4.1425. [DOI] [PubMed] [Google Scholar]
  25. Proebstle T. M., Fuchs T., Scheibenbogen C., Sterry W., Keilholz U. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients. Melanoma Res. 1998 Dec;8(6):557–563. doi: 10.1097/00008390-199812000-00011. [DOI] [PubMed] [Google Scholar]
  26. Richards J. M., Gale D., Mehta N., Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol. 1999 Feb;17(2):651–657. doi: 10.1200/JCO.1999.17.2.651. [DOI] [PubMed] [Google Scholar]
  27. Ronan S. G., Eng A. M., Briele H. A., Shioura N. N., Das Gupta T. K. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987 Oct;123(10):1326–1330. [PubMed] [Google Scholar]
  28. Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Seipp C. A., Einhorn J. H., White D. E., Steinberg S. M. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999 Mar;17(3):968–975. doi: 10.1200/JCO.1999.17.3.968. [DOI] [PubMed] [Google Scholar]
  29. Si Z., Hersey P., Coates A. S. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res. 1996 Jun;6(3):247–255. doi: 10.1097/00008390-199606000-00008. [DOI] [PubMed] [Google Scholar]
  30. Søndergaard K., Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases. Virchows Arch A Pathol Anat Histopathol. 1985;408(2-3):241–247. doi: 10.1007/BF00707986. [DOI] [PubMed] [Google Scholar]
  31. Tefany F. J., Barnetson R. S., Halliday G. M., McCarthy S. W., McCarthy W. H. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol. 1991 Aug;97(2):197–202. doi: 10.1111/1523-1747.ep12479662. [DOI] [PubMed] [Google Scholar]
  32. Thomas W. D., Hersey P. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int J Cancer. 1998 Jan 30;75(3):384–390. doi: 10.1002/(sici)1097-0215(19980130)75:3<384::aid-ijc10>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  33. Zehntner S., Townsend W., Parkes J., Schmidt C., Down M., Bell J., Mulligan R., O'Rourke M., Ellem K., Thomas R. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology. 1999 May;31(2):116–122. doi: 10.1080/003130299105296. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES